ロード中...
Treatment‐free remission with first‐ and second‐generation tyrosine kinase inhibitors
Chronic myeloid leukemia (CML) has become a chronic disease, for which the chronic phase is manageable with tyrosine kinase inhibitor (TKI) therapy. Patients with optimal responses to TKIs have achieved long‐term survival, and treatment‐free remission (TFR) has since become an additional treatment g...
保存先:
| 出版年: | Am J Hematol |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons, Inc.
2018
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6587857/ https://ncbi.nlm.nih.gov/pubmed/30394563 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25342 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|